Literature DB >> 2192851

Evening insulin strategy.

M C Riddle1.   

Abstract

A series of regimens based on intermediate-acting insulin given in the evening have been proposed as an alternative to conventional insulin therapy for non-insulin-dependent diabetes mellitus (NIDDM). This concept dates back to the earliest use of sustained-action insulin and has a rationale strengthened by recent physiological insights. Specifically, the predominance of fasting over postprandial hypoglycemia and occurrence of the dawn phenomenon in NIDDM argue for carefully timed overnight delivery of insulin. High nocturnal concentrations of free fatty acids in NIDDM may contribute to hepatic insensitivity to insulin and fasting hyperglycemia and can be suppressed by evening insulin. Although several clinical studies suggest that evening insulin regimens are safe and effective, their role in clinical practice is not yet established. Further study of this approach may clarify not only its proper use but also the best use of conventional strategies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2192851     DOI: 10.2337/diacare.13.6.676

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  8 in total

1.  Effects of a combination of bedtime intermediate-acting insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to respond to oral hypoglycaemic agents.

Authors:  M Krempf; T Godeau; S Ranganathan; P Blanchard; P Ritz; B Charbonnel
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Management of type 2 diabetes mellitus in the elderly: special considerations.

Authors:  J Rosenstock
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 3.  Dietary hyperglycemia, glycemic index and metabolic retinal diseases.

Authors:  Chung-Jung Chiu; Allen Taylor
Journal:  Prog Retin Eye Res       Date:  2010-09-22       Impact factor: 21.198

4.  Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin.

Authors:  Jung Seok Lee; Patrick Han; Rabib Chaudhury; Shihan Khan; Sean Bickerton; Michael D McHugh; Hyun Bong Park; Alyssa L Siefert; Gerald Rea; José M Carballido; David A Horwitz; Jason Criscione; Karlo Perica; Robert Samstein; Ragy Ragheb; Dongin Kim; Tarek M Fahmy
Journal:  Nat Biomed Eng       Date:  2021-10-06       Impact factor: 25.671

Review 5.  The role of sulphonylureas in the management of type 2 diabetes mellitus.

Authors:  Marc Rendell
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Basal insulin therapy.

Authors:  John N Clore; Linda Thurby-Hay
Journal:  Curr Diab Rep       Date:  2004-10       Impact factor: 4.810

Review 7.  Which basal insulin should be used in patients with type 2 diabetes mellitus?

Authors:  John N Clore; Linda Thurby-Hay
Journal:  Curr Diab Rep       Date:  2007-10       Impact factor: 4.810

8.  Adherence to Mediterranean Diet Is Associated With Better Glycemic Control in Children With Type 1 Diabetes: A Cross-Sectional Study.

Authors:  Jesus Dominguez-Riscart; Nuria Buero-Fernandez; Ana Garcia-Zarzuela; Celia Morales-Perez; Ana Garcia-Ojanguren; Alfonso M Lechuga-Sancho
Journal:  Front Nutr       Date:  2022-03-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.